2012•MD Conference ExpressRequires access

Apremilastin Patients with Psoriatic Arthritis: Results of the PALACE-1 Trial

Maria Vinall, Arthur Kavanaugh

Abstract

In PALACE-1 trial apremilast, an oral phosphodiesterase 4 inhibitor, was shown to be safe and effective in treating psoriatic arthritis (PsA) in subjects previously exposed to disease-modifying antirheumatic drugs. Apremilast modulates the production of pro- (tumor necrosis factor-a, natural killer cells, and epidermal keratinocytes) and anti-inflammatory mediators (interleukin-10), including those implicated in the etiopathogenesis of PsA.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Apremilast, Psoriatic arthritis, Medicine, Tumor necrosis factor alpha, Psoriasis, Dermatology, Arthritis, Antirheumatic drugs